Mark C. McKenna - 15 Feb 2023 Form 4 Insider Report for Prometheus Biosciences, Inc.

Role
Chairman, President & CEO, Director
Signature
/s/ Timothy K. Andrews, attorney-in-fact for Mark C. McKenna
Issuer symbol
N/A
Transactions as of
15 Feb 2023
Net transactions value
-$7,478,002
Form type
4
Filing time
17 Feb 2023, 20:31:13 UTC
Previous filing
19 Jan 2023
Next filing
03 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXDX Common Stock Options Exercise $72,500 +25,000 +45% $2.90* 80,144 15 Feb 2023 Direct F1
transaction RXDX Common Stock Sale $2,985,500 -25,000 -31% $119.42 55,144 15 Feb 2023 Direct F1, F2
transaction RXDX Common Stock Options Exercise $92,500 +25,000 +45% $3.70* 80,144 16 Feb 2023 Direct F1
transaction RXDX Common Stock Sale $2,996,750 -25,000 -31% $119.87 55,144 16 Feb 2023 Direct F1, F2
transaction RXDX Common Stock Options Exercise $50,616 +13,680 +25% $3.70* 68,824 17 Feb 2023 Direct F1
transaction RXDX Common Stock Sale $1,711,368 -13,680 -20% $125.10 55,144 17 Feb 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXDX Stock Option (Right to Buy) Options Exercise $0 -25,000 -7.5% $0.000000 308,633 15 Feb 2023 Common Stock 25,000 $2.90 Direct F1, F3
transaction RXDX Stock Option (Right to Buy) Options Exercise $0 -25,000 -4.7% $0.000000 506,725 16 Feb 2023 Common Stock 25,000 $3.70 Direct F1, F4
transaction RXDX Stock Option (Right to Buy) Options Exercise $0 -13,680 -2.7% $0.000000 493,045 17 Feb 2023 Common Stock 13,680 $3.70 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F3 25% of the shares subject to the option vested and became exercisable on September 9, 2020, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date.
F4 25% of the shares subject to the option vested and became exercisable on November 5, 2021, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date.